Sage stock plunges 18% post-market following business update, earnings (NASDAQ:SAGE)

Shares of Sage Therapeutics (NASDAQ:SAGE) fell 18% post-market after the company released its Q3 earnings report and said further development of its drug zuranolone for major depressive disorder has been scrapped.

Sage’s (SAGE) Q3 earnings were largely in line